These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22851483)

  • 1. Stuttering treated with olanzapine: a case report.
    Mozos-Ansorena A; Pérez-García M; Portela-Traba B; Tabernero-Lado A; Pérez-Pérez J
    Actas Esp Psiquiatr; 2012; 40(4):231-3. PubMed ID: 22851483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine for the treatment of acquired neurogenic stuttering.
    Catalano G; Robben DL; Catalano MC; Kahn DA
    J Psychiatr Pract; 2009 Nov; 15(6):484-8. PubMed ID: 19934725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alleviating stuttering with pharmacological interventions.
    Maguire GA; Yu BP; Franklin DL; Riley GD
    Expert Opin Pharmacother; 2004 Jul; 5(7):1565-71. PubMed ID: 15212606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute catatonia: Questions, diagnosis and prognostics, and the place of atypical antipsychotics].
    Belaizi M; Yahia A; Mehssani J; Bouchikhi Idrissi ML; Bichra MZ
    Encephale; 2013 Jun; 39(3):224-31. PubMed ID: 23095594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case Report of Stuttering Induced by Risperidone and Chlorpromazine.
    Sood S
    Psychopharmacol Bull; 2022 Feb; 52(1):53-56. PubMed ID: 35342201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acquired stuttering in a psychotic patient].
    Klein Hofmeijer-Sevink M; van Eijk ZJ; van der Zwaard R
    Tijdschr Psychiatr; 2009; 51(1):53-7. PubMed ID: 19194846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
    Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of stuttering: a critical review.
    Brady JP
    Am J Psychiatry; 1991 Oct; 148(10):1309-16. PubMed ID: 1680295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of "the premonitory state of schizophrenia" with atypical antipsychotics].
    Abekawa T; Kitaichi Y; Matsuyama T; Koyama T
    Seishin Shinkeigaku Zasshi; 2004; 106(11):1357-72. PubMed ID: 15700533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms].
    Menard ML; Yagoubi F; Drici M; Lavrut T; Askenazy F
    Encephale; 2013 May; 39 Suppl 1():S29-35. PubMed ID: 23219595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
    Liu-Seifert H; Osuntokun OO; Feldman PD
    Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
    J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S; Kornreich C; Choubani Z; Gourevitch R
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
    Moisan J; Grégoire JP
    Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valid grounds for the switch of original antipsychotics with generics.
    Ruzić K; Dadić-Hero E; Knez R; Medved P; Graovac M
    Psychiatr Danub; 2010 Mar; 22(1):102-4. PubMed ID: 20305601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
    Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
    J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
    Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
    Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.